HFA Submits Comments to IOM Survey on Essential Benefits
At the request of the Secretary of the Department of Health and Human Services, the Institute of Medicine (IOM) is doing a study that will make recommendations on the criteria and methods for determining and updating the essential health benefits package. The  IOM will review how insurers determine covered benefits, medical necessity and will provide […]
Biogen Idec Press Release: Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein
Click here for press releaseFirst Long-Lasting Factor VIII Candidate in Late-Stage Clinical Trial for Treatment of Hemophilia AWESTON, Mass. & STOCKHOLM, Dec 06, 2010 (BUSINESS WIRE) —Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that the first patient has been dosed with the companies’ long-lasting recombinant Factor VIII Fc fusion protein […]
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
Click here for study information
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Subjects With Hemophilia B
Click here for study information
English 
Español de Puerto Rico